Stay updated on Gantenerumab Long-term Safety in AD Clinical Trial
Sign up to get notified when there's something new on the Gantenerumab Long-term Safety in AD Clinical Trial page.

Latest updates to the Gantenerumab Long-term Safety in AD Clinical Trial page
- CheckyesterdayChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe site shows a revision update from v3.4.1 to v3.4.2. No changes to core study details or navigation are observed.SummaryDifference0.0%

- Check30 days agoChange DetectedA new revision tag (v3.4.1) was added and the previous revision (v3.4.0) removed; there are no changes to the study content or visible page information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check52 days agoChange DetectedRevision: v3.3.4 was added and the previous Revision: v3.3.3 was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check73 days agoChange DetectedLocations section expanded to include new regional sites across the US and internationally (Arizona, California, Florida, Michigan, New York, North Carolina, Oklahoma, Tennessee, Texas, South Australia, Victoria, Nova Scotia, Ontario, Emilia-Romagna, Lombardy, Mexico City, Nuevo León, Sankt-Peterburg, Alicante, Barcelona) and updated to v3.3.3; some previous location groupings were removed.SummaryDifference2%

- Check103 days agoChange DetectedThe page shows a new revision label 'Revision: v3.3.2' in place of the previous 'Revision: v3.2.0'. This looks like a frontend update and does not modify study details or other substantive content.SummaryDifference0.0%

Stay in the know with updates to Gantenerumab Long-term Safety in AD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Gantenerumab Long-term Safety in AD Clinical Trial page.